Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis

The induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+ regulatory T (Treg) cells, defined by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses. Quantitative and qualitative defects of Tregs have been postulated to contribute to failed immune regulation in multiple sclerosis (MS) and other autoimmune diseases. This paper highlights the potential uses of T regulatory cell epitopes (Tregitopes), natural Treg epitopes found to be contained in human immunoglobulins, as immunomodulating agents in MS. Tregitopes expand Treg cells and induce “adaptive Tregs” resulting in immunosuppression and, therefore, are being considered as a potential therapy for autoimmune diseases. We will compare Tregitopes versus intravenous immunoglobulin (IVIg) in the treatment of EAE with emphasis on the potential applications of Tregitope for the treatment of MS.

[1]  Anne S De Groot,et al.  Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. , 2011, Vaccine.

[2]  I. Raz,et al.  Prevention of type 1 diabetes: today and tomorrow , 2010, Diabetes/metabolism research and reviews.

[3]  C. Benoist,et al.  Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints , 2010, The Journal of experimental medicine.

[4]  J. Bluestone,et al.  IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells , 2010, The Journal of experimental medicine.

[5]  J. Kwekkeboom,et al.  Intravenous Immunoglobulins Promote Skin Allograft Acceptance by Triggering Functional Activation of CD4+Foxp3+ T cells , 2010, Transplantation.

[6]  Anne S De Groot,et al.  Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.

[7]  Ingo Müller,et al.  Dendritic cells: functional aspects of glycosylation and lectins. , 2009, Human immunology.

[8]  J. Ravetch,et al.  Identification of a receptor required for the anti-inflammatory activity of IVIG , 2008, Proceedings of the National Academy of Sciences.

[9]  D. Scott,et al.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.

[10]  S. Kaveri,et al.  Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. , 2008, Blood.

[11]  Ying Zhang,et al.  Abnormality of circulating CD4+CD25+ regulatory T cell in patients with Guillain–Barré syndrome , 2007, Journal of Neuroimmunology.

[12]  Y. Shoenfeld,et al.  Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function , 2007, The Journal of Immunology.

[13]  M. Sayegh,et al.  A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. , 2006, Journal of the American Society of Nephrology : JASN.

[14]  S. Anderton,et al.  Immunological tolerance using synthetic peptides--basic mechanisms and clinical application. , 2006, Current molecular medicine.

[15]  S. Nakae,et al.  IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[16]  K. Venken,et al.  Secondary progressive in contrast to relapsing‐remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T‐cell function and FOXP3 expression , 2006, Journal of neuroscience research.

[17]  S. Tridandapani,et al.  Molecular analysis of expression and function of hFcgammaRIIbl and b2 isoforms in myeloid cells. , 2006, Molecular immunology.

[18]  D. Scott,et al.  Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. , 2006, Cellular immunology.

[19]  P. Krammer,et al.  Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis , 2005, European journal of immunology.

[20]  Y. Shoenfeld,et al.  IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients , 2005, Autoimmunity.

[21]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[22]  A. Lovett-racke,et al.  Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. , 2004, Immunity.

[23]  H. Weiner.  Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. , 2004, Archives of neurology.

[24]  S. Szabo,et al.  Loss of T-bet, But Not STAT1, Prevents the Development of Experimental Autoimmune Encephalomyelitis , 2004, The Journal of experimental medicine.

[25]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[26]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[27]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[28]  D. Scott,et al.  In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment. , 2002, International immunology.

[29]  S. Reitan,et al.  Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[31]  S. Khoury,et al.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. , 2001, The Journal of clinical investigation.

[32]  C. Théry,et al.  The cell biology of antigen presentation in dendritic cells. , 2001, Current opinion in immunology.

[33]  K. Legge,et al.  Multi-Modal Antigen Specific Therapy for Autoimmunity , 2001, International reviews of immunology.

[34]  D. Scott,et al.  Mechanisms of Tolerance Induction by a Gene-Transferred Peptide-IgG Fusion Protein Expressed in B Lineage Cells1 2 , 2000, The Journal of Immunology.

[35]  H. Weiner,et al.  Multiple sclerosis vs Lyme disease: A case presentation to a discussant and a review of the literature , 1999, Multiple sclerosis.

[36]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[37]  A. Achiron,et al.  Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses , 1998, Neurology.

[38]  L. Wysocki,et al.  T cell recognition and tolerance of antibody diversity. , 1996, Journal of immunology.

[39]  D. Scott,et al.  Epitope-specific tolerance induction with an engineered immunoglobulin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[41]  T. Olsson,et al.  T Cells Recognizing Multiple Peptides of Myelin Basic Protein are Found in Blood and Enriched in Cerebrospinal Fluid in Optic Neuritis and Multiple Sclerosis , 1993, Scandinavian journal of immunology.

[42]  T. Olsson,et al.  Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. , 1990, The Journal of clinical investigation.

[43]  S. Jonjić,et al.  Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes , 1989, The Journal of experimental medicine.

[44]  G. Klaus,et al.  Differing effects of monoclonal anti-hapten antibodies on humoral responses to soluble or particulate antigens. , 1984, Immunology.

[45]  J. Cerottini,et al.  The immunosuppressive effect of passively administered antibody IgG fragments. , 1969, Journal of immunology.

[46]  Theobald. Smith.  ACTIVE IMMUNITY PRODUCED BY SO CALLED BALANCED OR NEUTRAL MIXTURES OF DIPHTHERIA TOXIN AND ANTITOXIN , 1909, The Journal of experimental medicine.

[47]  A. Sharabi,et al.  A New Model of Induced Experimental Systemic Lupus Erythematosus (SLE) in Pigs and Its Amelioration by Treatment with a Tolerogenic Peptide , 2009, Journal of Clinical Immunology.

[48]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[49]  S. White,et al.  RNAi-mediated chromatin silencing in fission yeast. , 2008, Current topics in microbiology and immunology.

[50]  R. Gold,et al.  Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues , 2007, Nature Clinical Practice Neurology.

[51]  A. Enk,et al.  Dendritic cells: key cells for the induction of regulatory T cells? , 2005, Current topics in microbiology and immunology.

[52]  M. Papamichail,et al.  Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function , 1986, European journal of immunology.